We are studying chemical modulators of cancer-relevant protein–protein interactions, comprising compounds that stabilize and others that destabilize the interactions. We employ both high-throughput screening and more rational drug design approaches for potential probe and drug identification, with subsequent characterization of the precise molecular modes of action and cellular effects of the bioactive compounds, ultimately utilizing them for basic research studies and possible drug development.